Locoregional Therapy for Cholangiocarcinoma

Nathan E. Frenk, MD1 Ronald S. Arellano, MD1

1 Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts


Address for correspondence Nathan Frenk, MD, Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, GRB 298, Boston, MA 02114 (e-mail: nfrenk@mgh.harvard.edu).

Hepatic resection and transplantation are the only potentially curative options for cholangiocarcinoma.1,2 Unfortunately, only approximately 30% of patients are considered surgical candidates at the time of diagnosis and the overall 5-year survival rates range from 33 to 65%.3 Given the dismal outcomes of systemic chemotherapy, other therapeutic options may have potential for patients with unresectable, recurrent, or metastatic disease.4,5 Thermal ablation or embolization may offer therapeutic options in selected patients with limited disease. Emerging early data suggest that by using principles of therapy used to treat other hepatic diseases, minimally invasive options may have a role in the treatment of selected cases of cholangiocarcinoma.6 This review explores emerging technologies and their potential role in treating cholangiocarcinoma.

Thermal Ablation
Thermal ablation has become a valuable treatment option for selected patients with primary or secondary hepatic tumors. Currently available thermal ablation options include radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. These modalities have been used primarily for the treatment of hepatocellular carcinoma (HCC), although some investigators have evaluated their role in the management of cholangiocarcinoma.

Radiofrequency Ablation
Radiofrequency ablation (RFA) is probably the most extensively used and investigated thermal ablation modality for the treatment of primary or metastatic liver tumors. RFA has shown clinical utility and acceptable tumor-free and overall survival benefits for selected patients with early stage HCC.6 Less extensively studied is the potential role and clinical benefit of RFA in management of cholangiocarcinoma. Nevertheless, emerging data suggest that the RFA may offer therapeutic benefits for intrahepatic cholangiocarcinoma (ICC). Early case reports describing intraoperative and percutaneous approaches were encouraging. In 2002, Slakey described the use of intraoperative RFA to treat a solitary intrahepatic recurrence that developed 12 months after resection of extrahepatic cholangiocarcinoma with right hepatic lobe involvement. Ten months after ablation, the patient remained free of detectable disease, thus raising the possibility that RFA might increase the number of patients considered surgically treatable.7 Similarly, Zgodzinski and
Espat described a single case of RFA to treat a solitary ICC in a patient who remained tumor-free for 24 months after treatment. Chiou et al reported ultrasound (US)-guided percutaneous RFA of 10 histologically proven cholangiocarcinomas that ranged in size from 1.9 to 6.8 cm and found that complete tumor necrosis could be achieved in a single treatment session for all tumors less than 3 cm in size, and had only one complication after 12 treatment sessions for all tumors. Giorgio et al reported similar results in a cohort of 10 patients, including 9 patients with primary ICC and 1 recurrence after resection, treated with US-guided RFA. Local control has been reported as high as 89% for recurrent or primary ICC.

**Cryoablation**

Limited clinical data exist on the use of cryoablation for treatment of cholangiocarcinoma. In general, cryoablation is used as one of the several palliative thermal ablation modalities for patients who are nonsurgical candidates. Most of the clinical data regarding cryoablation are embedded within studies that report the use of cryoablation for treatment of liver metastases. In a retrospective analysis of 57 patients with metastatic liver disease (41 colorectal and 16 non-colorectal) treated with cryoablation, Sheen et al used cryoablation to treat 57 patients with liver metastases and found that the median survival for patients with noncolorectal metastases was 37 months, compared with 22 months for patients with colorectal metastases.

**Microwave Ablation**

Microwave ablation (MWA) is emerging as an alternative to RFA for locoregional ablative therapy for primary and secondary liver malignancies (Fig. 1). The role of MWA for treatment of cholangiocarcinoma is yet to be defined, but early reports suggest clinical feasibility and safety. Xu et al reported overall survival rates for primary ICC of 87.5%, 75%, 62.5%, and 62.5% at 6, 12, 36, and 50 months, respectively. Yu et al reported cumulative overall 6-, 12-, and 24-month survival rates of 78.7%, 60%, and 60%, respectively. Similar survival rates were reported by Yang et al, who retrospectively evaluated 26 patients with advanced ICC treated with MWA and transarterial chemoembolization (TACE) and observed 6-, 12-, and 24-month survival rates of 88.5%, 69.2%, and 61.5%, respectively. Additionally, the overall complete ablation rate was reported as 92% with no major treatment-related complications.

![Fig. 1](A) Axial contrast-enhanced CT scan of the abdomen in a 75-year-old with recurrent intrahepatic cholangiocarcinoma (white arrow). (B) Axial unenhanced CT scan of the abdomen in a 75-year-old with recurrent intrahepatic cholangiocarcinoma. White arrow indicates microwave antenna within the tumor at time of microwave ablation (white arrow). (C) Axial contrast material-enhanced CT scan of the abdomen in a 75-year-old with recurrent intrahepatic cholangiocarcinoma. White arrow indicates post-MWA zone of ablation of ICC 1 month after ablation. No residual tumor was detected.
Embolization Techniques

Recurrence of cholangiocarcinoma after surgery is reportedly as high as 53%, with most recurrences developing within the liver. The role of transarterial therapies for their treatment is somewhat controversial, with most literature reporting some effectiveness as a palliative technique. In a multi-institutional analysis of intra-arterial therapy for advanced ICC, Hyder et al evaluated the safety and efficacy of TACE versus bland embolization versus radioembolization. Assessment of tumor response based on RECIST (Response Evaluation Criteria in Solid Tumors) criteria showed partial response in 21.5% patients whereas 61.5% patients had stable disease and only 13% showed progressive disease. Additionally, overall survival was no different between the various modalities and ranged from 10.5 to 14.3 months. Park et al compared TACE versus supportive care as palliative treatment in 155 patients with unresectable ICC and showed that TACE was associated with significantly improved survival of 12.2 months compared with supportive care alone. A preliminary study comparing the efficacy of drug-eluting beads preloaded with irinotecan (DEBIRI) or doxorubicin (DEBDOX) as second-line treatment for unresectable metastatic cholangiocarcinoma suggested a slightly overall survival benefit with DEBIRI, though the progression-free survival was 12.7 weeks with DEBIRI versus 15.8 weeks for DEBDOX. Overall, emerging data suggest that the best role for TACE is as a palliative technique with modest survival benefits compared with systemic therapies with acceptable safety profiles.

Radioembolization

Selective internal radiation therapy (SIRT) using yttrium-90-labeled microspheres is an emerging therapeutic option for management of cholangiocarcinoma (Fig. 2). Radioembolization is typically indicated when surgery, chemotherapy, or local thermal ablation are not therapeutic options. Radioembolization is a multistep procedure: (1) A baseline positron emission tomography–computed tomography (PET-CT) is obtained to document fluorine-18-deoxyglucose (FDG) activity of the hepatic lesion(s) and assess for extrahepatic disease. It is also critical for the evaluation of posttreatment results. The CT of the PET-CT study can also be used for tumor volumetric analysis that is required for calculating the dose of yttrium-90 to be administered. (2) Pre-SIRT visceral angiography is necessary to map the hepatic arterial anatomy and assess tumor vascularity. If

Fig. 2  (A) Axial gadolinium-enhanced MRI of the liver that demonstrates intrahepatic cholangiocarcinoma (white arrow). (B) Positron emission tomography-computed tomography (PET-CT) of intrahepatic cholangiocarcinoma that demonstrates focal area of increased FDG avidity that corresponds to tumor detected on MRI in Fig. 2A. (C) Digital subtraction hepatic arteriography at time of selective internal radiation therapy that demonstrates tumor blush (white arrows). (D) PET-CT of a 75-year-old with intrahepatic cholangiocarcinoma obtained 2 months following radioembolization. White arrow indicates absent FDG avidity in segment 4 that was FDG-avid prior to treatment (Fig. 2B).
necessary, deliberate embolization of the branches of the hepatic artery such as the gastroduodenal, superior pancreaticoduodenal, or right gastric arteries is performed to minimize the risk of nontarget embolization. Intra-arterial injection of technetium-99m macroaggregated albumin (MAA) is then given to assess for extrahepatic shunts. In general, patients with hepatopulmonary shunt fractions less than 20% are suitable for selective internal radiotherapy (SIRT). (3) A second visceral angiogram is then performed for selective delivery of yttrium-90 microspheres. For patients with bilobar disease, the pre-SIRT and SIRT procedures are usually performed separately for each lobe.

Emerging clinical data suggest promising results with SIRT for treating ICC.28–32 Prognostic factors such as tumor size, FDG avidity, and tumor burden appear to impact the effectiveness of radioembolization. Patients with lower tumor load, FDG-negative tumors, and smaller tumors appear to survive longer with radioembolization.32 Mosconi et al evaluated the use of yttrium-90 radioembolization for unresectable or recurrent ICC and showed that SIRT was associated with significantly longer survival in treatment-naive patients compared with patients who underwent previous surgery or other treatments.32 The combination of radioembolization and systemic chemotherapy may also have a role in downstaging initially unresectable patients to resection candidates. Rayar et al recently published a series of 49 patients with unresectable ICC treated with yttrium-90 and chemotherapy. Ten of whom 8 eventually underwent R0 resections.34 A meta-analysis of 12 studies with relevant data regarding SIRT showed that overall survival of patients with ICC treated with radioembolization is higher than historical survival rates and similar survival to patients treated with standard chemotherapy and/or TACE.35

References